EN DE
STOCK COMPARISON

J2KBIO Co. vs Linde plc Ordinary Shares: Fair Value & Quality

Both stocks run through our valuation models. Here is how J2KBIO Co. (420570) and Linde plc Ordinary Shares (LIN) compare, as of Aug 11, 2026.

As of Aug 11, 2026, Fair Value Calculator sees J2KBIO Co. as the less overvalued of the two: J2KBIO Co. trades at KRW 10,560 versus a fair value of KRW 9,142 (-13%), while Linde plc Ordinary Shares trades at $490 versus $222 (-55%).
J2KBIO Co.
420570.KQ · KRW · Basic Materials
-13%
upside to fair value
overvalued
PriceKRW 10,560
Fair ValueKRW 9,142
Quality53/100
Linde plc Ordinary Shares
LIN · USD · Materials
-55%
upside to fair value
overvalued
Price$490
Fair Value$222
Quality70/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

J2KBIO Co.Linde plc Ordinary Shares
Valuation
P/E (TTM)34.1×
P/S (TTM)6.95×
P/B6.30×
EV/EBITDA18.9×
PEG2.18×
3.0%Dividend yield1.2%
KRW 250Dividend per share$6.10
Profitability
11%Net margin20%
17%Operating margin28%
12%Return on equity18%
7%Return on assets7%
Growth
53%Revenue growth (YoY)8%
27.2%Avg. growth/yr (3Y)0.6%
Avg. growth/yr (5Y)4.5%
Balance & size
0.01×Debt / equity0.54×
$32MMarket cap$241B
mixedGrowth qualityhealthy

J2KBIO Co. leads: 5 to 3 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

J2KBIO Co.of which business quality 55 · market factors 58 Linde plc Ordinary Sharesof which business quality 66 · market factors 61
ProfitabilityMargins and returns on capital today
51
51
Quality GrowthAre margins and returns improving?
50
51
CashflowEarnings quality: real cash, not paper profit
24
64
Fin. StrengthBalance sheet, leverage, solvency risk
100
69
InvestmentDisciplined investing over empire-building
31
70
Low VolatilityCalm price path (market factor)
60
87
MomentumPrice trend over the last 3–12 months (market factor)
57
48
52W MomentumDistance to the 52-week high (market factor)
60
52
Net IssuanceBuybacks instead of dilution
63
100

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

J2KBIO Co.

DCF ModelsKRW 12,217
Earnings-BasedKRW 8,049
MultiplesKRW 8,831
Asset-BasedKRW 3,870
Growth DCFKRW 8,490
Economic ProfitKRW 6,244
Growth EarningsKRW 11,223

15 of 24 models see the stock below the current price.

Linde plc Ordinary Shares

DCF Models$211
Earnings-Based$132
Dividend Discount$116
Multiples$239
Asset-Based$55.42
Growth DCF$155
Economic Profit$156
Growth Earnings$204

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

J2KBIO Co.
Bear KRW 6,856Fair Value KRW 9,142Bull KRW 11,427
KRW 10,560 = current price (white tick)
Linde plc Ordinary Shares
Bear $121Fair Value $222Bull $291
$490 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

J2KBIO Co. · Basic Materials

Quality score53 · above median
Fair value upside-13% · above median

Linde plc Ordinary Shares · Materials

Quality score70 · Top 25%
Fair value upside-55% · below median

Bottom line

As of Aug 11, 2026, Fair Value Calculator sees J2KBIO Co. as the less overvalued of the two: J2KBIO Co. trades at KRW 10,560 versus a fair value of KRW 9,142 (-13%), while Linde plc Ordinary Shares trades at $490 versus $222 (-55%).

Linde plc Ordinary Shares has the higher quality score (70/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.